IB are used to restrict any kind of collaboration and Teams communication between two internal segments of users within an organization. IB offers a comprehensive detect, alert, and remediate mechanism and is applicable to MS Teams, SharePoint, One Drive for business and...
Assignment of interventions: allocation Sequence generation The statistician will generate the random list by block randomization with variable block length, implemented using the PROC PLAN for SAS 9.4 statistical software. Concealment mechanism After the sequence is generated, Dr. Zhiying Zhan performs a...
In Table 1, we have summarized eight USFDA-approved small molecules for the AD to date to have an overview. Table 1. List of USFDA approved small molecules for the treatment of AD. Brand nameDrugDrug Target & MOADosingAdverse EffectsWebsite Adbry Tralokinumab-ldrm IL-13 Inhibitor: ...
Douillard J, Rosell R, Delena M: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006, 7: 719-727. 10.1...
Table 2. List of ongoing trials investigating DDR inhibitors in patients in lymphoma, ranked by the drugs’ targets and by trial status in May 2020. TargetTitleRegistration NumberStatus *First Posted *PhaseConditions * WEE1 Adavosertib NCT01748825 Active, not recruiting 2012 Phase 1 Advanced solid...
yum@kist.re.kr 1 Clean Energy Research Center, Korea Institute of Science and Technology (KIST), Hwarangno 14‑gil 5, Seongbuk‑gu, Seoul 02792, South Korea Full list of author information is available at the end of the article of antibiotics, hormones, and vitamins; and a swel...
Currently approved type Ib MET-TKIs, capmatinib and tepotinib, interact with the residue Y1230 residue; thus, it is reasonable that secondary mutations at Y1230 cause resistance to these drugs. In addition, through analyses of clinical specimens obtained from patients who acquired resistance to typ...
Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of UPA over 24 weeks and identify clinical predictors of response, in a multicentric cohort of patient...
In this multi-center phase II trial, we evaluated the efficacy and safety of a quadruplet regimen (pembrolizumab, trastuzumab, and doublet chemotherapy) as first-line therapy for unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC) (NCT...
We also use optional cookies for advertising, personalisation of content, usage analysis, and social media. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with...